Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).
Women more likely to experience first fragility hip fracture in their 60s
Older women with low bone density are more likely to experience their first hip fracture in their 60s compared to older ages, according to research
June 3, 2024